MetLife Investment Management’s Repligen RGEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.48M Sell
25,532
-788
-3% -$96.8K 0.02% 842
2026
Q1
$3.1M Buy
26,320
+154
+0.6% +$21.5K 0.02% 831
2025
Q4
$4.29M Sell
26,166
-1,321
-5% -$207K 0.02% 694
2025
Q3
$3.67M Sell
27,487
-954
-3% -$116K 0.02% 776
2025
Q2
$3.54M Sell
28,441
-903
-3% -$115K 0.02% 727
2025
Q1
$3.73M Sell
29,344
-430
-1% -$66.2K 0.02% 759
2024
Q4
$4.29M Buy
29,774
+2,428
+9% +$348K 0.02% 650
2024
Q3
$4.07M Sell
27,346
-454
-2% -$65.1K 0.02% 642
2024
Q2
$3.5M Sell
27,800
-1,810
-6% -$284K 0.02% 685
2024
Q1
$5.45M Sell
29,610
-750
-2% -$143K 0.04% 441
2023
Q4
$5.46M Sell
30,360
-451
-1% -$70.2K 0.04% 411
2023
Q3
$4.9M Sell
30,811
-1,317
-4% -$215K 0.04% 413
2023
Q2
$4.54M Sell
32,128
-1,184
-4% -$190K 0.03% 501
2023
Q1
$5.61M Sell
33,312
-842
-2% -$150K 0.04% 386
2022
Q4
$5.78M Sell
34,154
-699
-2% -$127K 0.04% 364
2022
Q3
$6.52M Sell
34,853
-364
-1% -$76.8K 0.05% 296
2022
Q2
$5.72M Sell
35,217
-408
-1% -$64.5K 0.04% 360
2022
Q1
$6.7M Buy
35,625
+10,707
+43% +$2.03M 0.04% 365
2021
Q4
$6.6M Buy
24,918
+355
+1% +$95.6K 0.05% 303
2021
Q3
$7.1M Sell
24,563
-951
-4% -$244K 0.06% 253
2021
Q2
$5.09M Sell
25,514
-797
-3% -$155K 0.04% 372
2021
Q1
$5.12M Sell
26,311
-1,231
-4% -$252K 0.05% 377
2020
Q4
$5.28M Sell
27,542
-414
-1% -$75.3K 0.05% 338
2020
Q3
$4.12M Hold
27,956
0.05% 379
2020
Q2
$3.46M Sell
27,956
-20,801
-43% -$2.45M 0.04% 462
2020
Q1
$4.71M Sell
48,757
-706
-1% -$68.2K 0.06% 273
2019
Q4
$4.58M Sell
49,463
-81
-0.2% -$6.8K 0.05% 397
2019
Q3
$3.8M Buy
49,544
+28,368
+134% +$2.48M 0.04% 470
2019
Q2
$1.82M Sell
21,176
-31,618
-60% -$2.16M 0.02% 861
2019
Q1
$3.12M Buy
52,794
+35,196
+200% +$2.02M 0.01% 1043
2018
Q4
$928K Hold
17,598
0.01% 1046
2018
Q3
$976K Hold
17,598
0.01% 1133
2018
Q2
$828K Hold
17,598
0.01% 1111
2018
Q1
$637K Hold
17,598
0.01% 1231
2017
Q4
$638K Buy
+17,598
New +$637K 0.01% 1262

Other funds holding RGEN

MetLife Investment Management's RGEN Position: Q2 2026 in Review

MetLife Investment Management reduced its Repligen (RGEN) stake by 3% in Q2 2026, selling an estimated $96.8K and leaving 25,532 shares worth $3.48M. The position accounts for 0.02% of the portfolio, ranked #842.

MetLife Investment Management first reported a position in RGEN in Q4 2017 and has held it in 35 quarters since. The position peaked at $7.1M in Q3 2021. 477 funds tracked by Wall St. Rank hold RGEN as of Q2 2026.

  • MetLife Investment Management held 25,532 shares of Repligen worth $3.48M as of Q2 2026.
  • MetLife Investment Management sold 788 Repligen shares in Q2 2026, an estimated $96.8K.
  • Repligen made up 0.02% of MetLife Investment Management's portfolio in Q2 2026, its #842 holding.
  • MetLife Investment Management first reported a position in Repligen in Q4 2017 and has held it in 35 quarters since.
  • MetLife Investment Management's Repligen position peaked at $7.1M in Q3 2021.
  • 477 funds tracked by Wall St. Rank held Repligen as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.